Prognostic and clinicopathological significance of long noncoding RNA HOXA11-AS expression in human solid tumors: a meta-analysis

Table 1 Characteristics of studies included in the meta-analysis

Authors	Years	Region	Tumor type	Sample type	Sample size	Preoperative treatment	Tumor stage	Method of HOXA11-AS expression	Elevated HOXA11-AS	Cut-off value	Outcome measure	Survival analysis^a	Method^b	NOS score
Kim et al.	2016 [14, 17]	Korea	Cervical cancer	Tissues	92	No	FIGO I–III	qRT-PCR	Significantly higher (p < 0.05)	Tenfold	OS	U, M	1	8
Sun et al.	2016 [31]	China	Gastric cancer	Tissues	86	No	TNM I–IV	qRT-PCR	Significantly higher (p < 0.01)	Median	OS, PFS	U, M	1, 2	8
Wang et al.	2016 [26]	China	Glioblastoma	Tissues	89	N/A	N/A	N/A	Significantly higher (p < 0.01)	Median	OS	U, M	1	6
Chen et al.	2017 [9, 27]	China	Non-small cell lung cancer	Tissues	78	No	TNM I–III	qRT-PCR	Significantly higher (p < 0.05)	Median	OS	No	2	7
Cui et al.	2017 [16, 28]	China	Osteosarcoma	Tissues	51	No	TNM I–III	qRT-PCR	Significantly higher (p < 0.05)	Median	OS	No	1	6
Xu et al.	2017 [32]	China	Glioma	Tissues	45	N/A	TNM I–IV	qRT-PCR	Significantly higher (p < 0.01)	Median	OS	No	1	7
Yim et al.	2017 [29]	Korea	Serous ovarian cancer	Tissues	129	No	FIGO I–IV	qRT-PCR	Significantly higher (p < 0.05)	Fold change	OS, PFS	M	1	7
Zhang et al.	2017 [30]	TCGA	Lung adenocarcinoma	N/A	287	N/A	TNM I–IV	N/A	Significantly higher (p < 0.001)	N/A	OS	No	2	6
Zhang et al.	2017 [30]	TCGA	Lungsquamous cell carcinoma	N/A	463	N/A	TNM I–IV	N/A	Significantly higher (p < 0.001)	N/A	OS	No	2	6

N/A not available, TNM tumor/node/metastasis, FIGO International Federation of gynecology and obstetrics, qRT-PCR quantitative reverse transcription PCR, OS overall survival, PFS progression free survival, NOS Newcastle–Ottawa Scale
^aU denoted as univariate analysis; M denoted as multivariate analysis
^b1 denoted as obtaining HRs directly from publications; 2 denoted as extracting HRs from Kaplan–Meier curves

ISSN: 1475-2867